Douglass Winthrop Advisors LLC Raises Stock Holdings in Danaher Co. (NYSE:DHR)

Douglass Winthrop Advisors LLC lifted its stake in Danaher Co. (NYSE:DHRFree Report) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,603 shares of the conglomerate’s stock after purchasing an additional 587 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Danaher were worth $17,027,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cape Investment Advisory Inc. purchased a new position in shares of Danaher in the 4th quarter worth about $25,000. BKM Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. purchased a new position in shares of Danaher in the 4th quarter worth $29,000. Rakuten Securities Inc. bought a new stake in shares of Danaher in the fourth quarter worth $36,000. Finally, Financial Connections Group Inc. purchased a new stake in Danaher during the fourth quarter valued at $41,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR traded up $1.38 during midday trading on Monday, hitting $262.78. 2,089,000 shares of the company traded hands, compared to its average volume of 2,693,784. The stock has a market cap of $194.64 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 4.02 and a beta of 0.83. The firm has a 50 day moving average of $250.19 and a 200-day moving average of $239.72. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $268.98.

Danaher (NYSE:DHRGet Free Report) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.36 earnings per share. On average, analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Analysts Set New Price Targets

DHR has been the subject of a number of recent research reports. TD Cowen boosted their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Raymond James upped their target price on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Citigroup lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird upped their price objective on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, KeyCorp lifted their target price on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $267.31.

Get Our Latest Research Report on DHR

Insider Activity at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock valued at $37,536,717 over the last 90 days. 10.90% of the stock is owned by corporate insiders.

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.